ImmuSmol is launching today a range of preclinical services in the field of cancer immunotherapy under the brand Explicyte Immuno-Oncology.
Explicyte Immuno-Oncology currently offers to test innovative cancer immunotherapies in vivo, using syngeneic mouse tumor models treated with immune checkpoint inhibitors (eg. anti-CTLA-4 and anti-PD1/PD-L1 antibodies). In addition, Explicyte is setting up an in vitro platform for the identification and optimization of novel immunomodulators. Equipped with high-content analysis technologies, the platform will focus on live phenotypic screening in co-cultures of immune and cancer cells, as well as molecular cell-based assays for the assessment of immune checkpoint inhibitors.
